High pericardial and peri-aortic adipose tissue burden in pre-diabetic and diabetic subjects

Fei-Shih Yang1, Chun-Ho Yun1,2, Tung-Hsin Wu2, Ya-Ching Hsieh3, Hiram G Bezerra4, Chuan-Chuan Liu5,6,7, Yih-Jer Wu8,9,10, Jen-Yuan Kuo8,9, Chung-Lieh Hung5,8,9, Charles Jia-Yin Hou8,9, Hung-I Yeh8,9, Jason Jeun-Shenn Lee2, Bernard E Bulwer11,12 and Ricardo C Cury13†

Abstract

Background: Central obesity in relation to insulin resistance is strongly linked to the development of type 2 diabetes. However, data regarding the association between pericardial and peri-aortic adiposity, a potential estimate of visceral adipose tissue burden, and pre-diabetes status remains unclear. The aim of this study was to examine whether the degree of pericardial and thoracic peri-aortic adipose tissue, when quantified by multi-detector computed tomography (MDCT), differs significantly in a normal, pre-diabetic, and overtly diabetic population.

Methods: We studied 562 consecutive subjects including 357 healthy, 155 pre-diabetic, and 50 diabetic patients selected from participants who underwent annual health surveys in Taiwan. Pre-diabetes status was defined by impaired fasting glucose or impaired glucose intolerance according to American Diabetes Association guidelines. Pericardial (PCF) and thoracic peri-aortic (TAT) adipose tissue burden was assessed using a non-contrast 16-slice multi-detector computed tomography (MDCT) dataset with off-line measurement (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). Body fat composition, serum high-sensitivity C-reactive protein (hs-CRP) level and insulin resistance (HOMA-IR) were also assessed.

Results: Patients with diabetes and pre-diabetes had greater volume of PCF (89 ± 24.6, 85.3 ± 28.7 & 67.6 ± 26.7 ml, p < 0.001) as well as larger TAT (9.6 ± 3.1 ml vs 8.8 ± 4.2 & 6.6 ± 3.5 ml, respectively, p < 0.001) when compared to the normal group, although there were no significant differences in adiposity between the diabetic and pre-diabetic groups. For those without established diabetes in our study, increasing TAT burden, but not PCF, appear to correlate with insulin resistance (HOMA-IR) and hs-CRP in the multivariable models.

Conclusions: Pre-diabetic and diabetic subjects, compared to normoglycemia, were associated with significantly higher pericardial and peri-aortic adipose tissue burden. In addition, visceral fat accumulation adjacent to the thoracic aorta seemed to exert a significant impact on insulin resistance and systemic inflammation.

Keywords: Pre-diabetes, Diabetes mellitus, MDCT, Pericardial adipose tissue, Peri-aortic adipose tissue, Insulin resistance

Background

Central obesity is a risk factor of metabolic syndrome, type 2 diabetes, and hyperlipidemia [1]. In the past decade, studies have focused on the relationship between metabolic derangements and regional fat deposits, particularly located in the trunk and waist area independent of total adiposity. Due to recent advances in radiological techniques, adiposity is readily assessable by computed tomography (CT), which may be a more direct measure of tissue burden. Based on this technique, more and more researches focus on ectopic visceral fat located between the myocardium and pericardium (pericardial) as well as those adjacent to the thoracic aorta (peri-aortic) in recent years. Visceral adipose tissues may play an important role in cardiovascular diseases and metabolic derangements such as diabetes, mainly due to the secretion of pro-inflammatory mediators and cytokines, as a consequence of the liver
releasing of free fatty acids (FFAs) into the portal, leading to insulin resistance and systemic inflammation [2,3].

Pre-diabetes is characterized by impaired fasting glucose or impaired glucose tolerance status that reflects the stage of disordered glucose metabolism between normoglycemia and diabetes. Pre-diabetes is often under detected and remains asymptomatic, which may elevate future risks of diabetes and cardiovascular complications [4]. Recently, studies have shown that excessive adipose tissue deposits were closely related to diabetes development [5,6]. In addition, exaggerated systemic inflammation in response to excessive visceral adipose tissue had been proposed as the main mediating factor in pancreas functional failure, which plays a key role in type 2 diabetes. However, the relationship between visceral adipose tissue and pre-diabetes status before established clinical diabetes remains unknown. In this regard, the main objectives in this study were two-fold; first, we examined whether there are significant differences and distribution of PCF, TAT between subjects with pre-diabetes or diabetes. Second, we further aimed to examine whether VAT, either PCF or TAT, may still correlate several clinical cardiometabolic risks even in subjects without clinically overt diabetes.

Methods
Study subjects
The study was approved by the Institutional Review Board of Mackay Memorial Hospital, Taipei, Taiwan. The reference number is 09MMHIS028. All participants signed written informed consent prior to examinations. Data were analyzed anonymously. From 2005 to 2009, a total of 562 participants including 357 healthy, 155 with pre-diabetes and 50 with type 2 diabetes underwent health survey and received non-contrast enhanced computed tomography (CT) for assessment of cardiovascular risks by calculating coronary artery calcium in our center. All participants were consecutively enrolled using the following criteria and divided into three groups: normal (subjects without hypertension, type 2 diabetes, hyperlipidemia), pre-diabetes (impaired fasting glucose (IFG), impaired glucose intolerance, or IFG + IGT) and type 2 diabetes defined by the American Diabetes Association guidelines [7]. We further excluded subjects who had typical anginal symptoms during exercise or known cardiovascular diseases including myocardial infarction, coronary arterial disease, stroke, atrial fibrillation, prior hospitalization for congestive heart failure, and peripheral arterial disease.

Demographic, anthropometric indices, and laboratory measures
Detailed physical examination was performed as well as a thorough review of baseline demographics, medical history including alcohol consumption, smoking, and physical activity status from structured questionnaires. All baseline characteristics and anthropometric measures including age, body height, body weight, waist, and buttock circumferences were all collected. Standardized sphygmomanometer cuff-defined resting blood pressures were measured under resting conditions by medical staff blinded to other test results. Body surface electrocardiogram (ECG) from 12-leads was performed for all subjects. The estimate of metabolic scores was calculated and presented as the numbers of abnormal items of the NCEP Panel III criteria (ATP III) based on measures of waist circumference (Female > =80 cm or Male > =90 cm), fasting glucose (≥ 100 mg/dL), HDL cholesterol (Male < 40 mg/dL or Female < 50 mg/dL), triglyceride (> 150 mg/dL) and blood pressure (> 130/85 mmHg). High-sensitivity C-reactive protein (hs-CRP) levels were determined by using a highly sensitive, latex particle-enhanced immunoassay Elecsys 2010 (Roche, Mannheim, Germany).

Glucose metabolism
All sample collection and analytic principles were based on the standard requirements according to the Clinical Laboratory Standards Institute (CLSI) guidelines (Specimen Choice, Collection, and Handling: Approved Guideline H18-A3). To ensure accuracy, samples had repeated tests in their original tubes within one day to avoid sample mix up. Normoglycemia was defined as fasting serum glucose (FSG) less than 100 mg/dL. Pre-diabetes was defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) using the American Diabetes Association diagnostic criteria [7]. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated.

CT scan and quantification of pericardial and thoracic peri-aortic fat
MDCT of the coronary calcium was performed using a 16-slice MDCT scanner (Sensation 16, Siemens Medical Solutions, Forchheim, Germany) with 16 x 0.75 mm collimation, rotation time 420 ms and tube voltage of 120 kV. In one breath-hold, images were acquired from above the level of the tracheal bifurcation to below the base of heart using prospectively ECG triggering with the centre of the acquisition at 70% of the R-R interval. Visceral adipose tissue, PCF and TAT, was quantified by MDCT using a dedicated workstation (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). The semi-automatic segmentation technique was developed for quantification of fat volumes. We traced the region of interest manually and defined fat tissue as pixels within a window from -195 HU to -45 HU and a window center at -120 HU. PCF was defined as any adipose tissue located within the pericardial sac. TAT tissue was defined as all of the adipose tissue surrounding the
thoracic aorta, which extended 67.5 mm from the level of the bifurcation of pulmonary arteries with cranial-caudal coverage of the thoracic aorta. This approach has previously been validated [6,8,9]. Initially, the intra-observer and inter-observer coefficient of variation were 4.27%, 4.87% and 6.58%, 6.81% for PCF and TAT, respectively. Both observers performed an independent reading in a random subset of 40 subjects [6].

Statistical analysis
Continuous data were expressed as the mean and standard deviation with categorical data expressed as the frequency and proportion of occurrence. Differences in baseline demographics between groups were tested by Student t- test with categorical data analyzed by chi-square or Fisher’s exact test as appropriate. Wilcoxon non-parametric trend test was used to estimate the trend of all continuous data and ordinal variables across all ordered groups. Univariable logistic regression model was used to determine the significant factors in the prediction of different metabolic components stratified by both visceral adipose tissue and hs-CRP tertiles with individual odds ratio (OR), significance (p value), and 95% confidence interval (CI) reported. A multivariable regression model in subjects without overt diabetes was conducted to identify the independent role of visceral adipose in predicting hs-CRP level and HOMA-IR after adjustment for baseline clinical variables, various body size estimates, and biochemical data. The variables enrolled in multivariable models were chosen from those clinical covariates with significant associations with both visceral adipose tissue in univariate regressions. Due to collinearity, various body size estimates including BMI, BSA, waist circumference and body fat composition information were sequentially entered into multivariable models. All data was analyzed by commercialized software STATA 8.2 package (STATA Corp., College Station, Texas). The significance of p level (α-value) for all analysis was two-sided with 0.05 considered to be statistically significant.

Result
Study sample characteristics
Table 1 describes the demographic anthropometric and laboratory measures for all subjects included in this study. A total of 562 participants were enrolled: 357 healthy, 155 with pre-diabetes and 50 with type 2 diabetes. Both pre-diabetic and type 2 diabetic subjects were significantly older with higher blood pressure, weight, body mass index, waist circumferences, waist-to-hip ratio than the normal group (all p < 0.001). While no significant differences in body fat composition were found between subjects with pre-diabetes and normal subjects. In addition, triglyceride, fasting glucose, post-prandial glucose, HbA1c, and HOMA-IR were higher with a lower HDL cholesterol level in subjects with pre-diabetes and type 2 diabetes, when compared with normal ones (all p < 0.001). Patients who had type 2 diabetes had differed significantly from ones with pre-diabetes with higher triglyceride, fasting glucose, postprandial glucose, HbA1c, and HOMA-IR as well as had lower HDL cholesterol levels. The mean value of PCF and TAT were 85.3 ± 28.7 & 8.8 ± 4.2 ml in pre-diabetic subjects and 89 ± 24.6 & 9.6 ± 3.1 ml in type 2 diabetic subjects, respectively, and were significantly higher than both VAT in normals (67.6 ± 26.7 ml & 6.6 ± 3.5 ml, all p < 0.001). However, both VAT were not different between pre-diabetic and type 2 diabetic subjects in Figure 1A and B. The difference among normal, pre-diabetic, and type 2 diabetic subjects for hs-CRP are shown in Figure 1C. Subjects with pre-diabetes and type 2 diabetes had higher hs-CRP than normals (all p < 0.001). There was no significant difference between pre-diabetes and type 2 diabetes in hs-CRP.

In Table 2, we examined the association between both VAT and clinical continuous and dichotomous variables for subjects without established type 2 diabetes (N = 512). We observed that both VAT were positively associated with increasing age, and body size estimates (including BMI, BSA, waist circumference), body fat composition, systolic blood pressure, and fasting glucose level (all p < 0.001). Furthermore, both VAT were associated with higher triglyceride, lower HDL cholesterol (both p < 0.001) and higher LDL cholesterol (both p = 0.004). In Table 3, we further examined these associations in multivariable models. Both VAT were associated with higher HOMA-IR, hs-CRP in univariable model. When age, gender, various anthropometric measures, and clinical variables were further adjusted, we observed that the relationship between PCF and HOMA-IR, hs-CRP remained borderline (p > 0.03& <0.1). Increasing TAT burden correlated with higher HOMA-IR, hs-CRP (all p < 0.05) in the multivariable models.

Discussion
Our study provides new insights into the understanding of the association of visceral adipose tissue, PCF and TAT, among persons with pre-diabetes, type 2 diabetes, and normoglycemia. It has been demonstrated that people with pre-diabetes are at significantly more risk of developing cardiovascular disease than those with normoglycemia, and will likely develop type 2 diabetes without intervention [10]. Central or visceral obesity is associated with increased insulin resistance, type 2 diabetes, hypertension, and hyperlipidemia. In an earlier work, Stancakova et al. [11] found that an increased waist circumference, the estimation of visceral adiposity in male among pre-diabetes. Recently, the association between diabetes and pericardial/epicardial adiposity
measured by echocardiography and MDCT has been examined in several studies [2,6,12]. Using echocardiography, Iacobellis et al. observed a significant association between epicardial fat thickness and fasting blood glucose [12]. However, most of these studies did not show a significant difference in visceral adiposity in individuals with pre-diabetes compared to those with type 2 diabetes. Our data adds value to previous reports particularly establishing the association between visceral adiposity and glucose intolerance. Compared to a previous study [12], we used volume-based measures for assessing region-specific visceral adipose tissue surrounding the heart and thoracic

Table 1 The baseline demographic data of participants according to glucose tolerance status

|                       | No diabetes | Pre-DM | DM | Trend P |
|-----------------------|-------------|--------|----|---------|
| Age                   | 47.5 ± 7.7  | 51 ± 8 | 53.5 ± 8 | <0.001  |
| Gender, female        | 127 (35.6%) | 22 (14%) | 12 (24%) | <0.001  |
| SBP, mmHg             | 116.9 ± 15.4| 124.6 ± 16.8 | 130.2 ± 16.7 | <0.001  |
| BMI, kg/m²             | 23.6 ± 3.1  | 25.3 ± 3.1 | 26.2 ± 3.8 | <0.001  |
| BSA, m²               | 1.72 ± 0.17 | 1.8 ± 0.16 | 1.81 ± 0.15 | <0.001  |
| WC, cm                 | 81 ± 8.9    | 86.9 ± 8.3 | 89.2 ± 8.7 | <0.001  |
| Body Fat, %            | 24.9 ± 6.2  | 25.9 ± 6.2 | 27.3 ± 9.1 | 0.08     |
| PCF, ml                | 68.2 ± 25.5 | 86.8 ± 26.9 | 91 ± 24.1 | 0.005    |
| TAT, ml               | 6.4 ± 3.3   | 8.7 ± 4.2 | 9.5 ± 3.2 | 0.005    |
| Hypertension           | 30 (7.7%)   | 27 (17.5%) | 17 (34%) | <0.001  |
| Hyperlipidemia         | 14 (3.6%)   | 9 (5.8%) | 5 (10%) | 0.157    |
| Smoking                | 83 (21.3%)  | 38 (24.7%) | 16 (32%) | 0.172    |
| Fasting Glucose, mg/dL | 91.6 ± 5.7  | 103.6 ± 8.8 | 159.7 ± 52.7 | <0.001  |
| Post-prandial Glucose, mg/dL | 99.3 ± 15.7 | 117.5 ± 30.1 | 205.2 ± 85.9 | <0.001  |
| HbA1c, %               | 5.67 ± 0.32 | 5.93 ± 0.41 | 7.52 ± 1.85 | <0.001  |
| HOMA-IR                | 1.25 ± 0.85 | 1.81 ± 1.09 | 3.42 ± 2.27 | <0.001  |
| Uric Acid, mg/dL       | 5.58 ± 1.37 | 6.35 ± 1.48 | 6.04 ± 1.28Y | <0.001  |
| Total Cholesterol, mg/dL | 192.5 ± 33.9 | 195.1 ± 31.9 | 191.2 ± 39.7 | 0.79     |
| TG, mg/dL              | 126.4 ± 65.1 | 145.3 ± 85.6 | 204.6 ± 158.5 | <0.001  |
| LDL cholesterol, mg/dL | 125.2 ± 31  | 128.8 ± 31 | 122.8 ± 32 | 0.67     |
| HDL cholesterol, mg/dL | 53.5 ± 13.5 | 49.8 ± 13.4 | 44.1 ± 9.3Y | <0.001  |
| BUN, mg/dL             | 11.9 ± 3.6  | 12.6 ± 3.4 | 13.1 ± 3.7Y | <0.001  |
| eGFR, mL/min/1.73 m²   | 86.9 ± 14.4 | 81.5 ± 13.3 | 84.8 ± 20.2 | 0.31     |

ANOVA: *p < 0.05 compared to No Diabetes group, ¥p < 0.05 compared to Pre-DM group, *p >=0.05 & <0.1 compared to No Diabetes group. BMI body mass index, HbA1c glycosylated hemoglobin, TG triglyceride, LDL cholesterol low-density cholesterol, HDL cholesterol high-density cholesterol, eGFR estimated glomerular filtration rate, WC waist circumference.

Figure 1 The correlation between normal, pre-diabetic, diabetic subjects and TAT (A), PCF (B) and hs-CRP (C).
aorta by multi-detector computed tomography, a more precise measure. Additionally, we extended these previous observations by showing that PCF and TAT are significantly increased in pre-diabetic individuals compared to normals, with no significant differences observed between individuals with type 2 diabetes and those with pre-diabetes. Interestingly, we observed similar trends in the associations regarding both region-specific VAT and several clinical metabolic risks and clinical co-variates as previous report in our current cohort [13]. This information suggests progressive metabolic derangements with increasing degrees of visceral adiposity, leading to a progression from early glycemic dysfunction to the pre-diabetes stage, in tandem with increasing CVD risk. The volume-based, three-dimensional CT measurement may be a useful tool for diabetes-related cardiovascular risk stratification in selected subjects.

How is visceral fat related to glucose deregulation? Increased abdominal visceral adiposity, rather than peripheral subcutaneous adiposity, has been associated with glucose intolerance or frank diabetes [14]. Bays et al. [15] has hypothesized the pathologic role of visceral adipose tissue as "sick fat". This hypothesis states that "adiposopathy" is promoted by positive caloric balance and sedentary lifestyle in genetically susceptible individuals. The accumulation of visceral adipose tissue is associated with adverse endocrine and immune consequences due to released substances such as free fatty acids, leptin, adiponectin, pro-inflammatory agents, and decreased anti-inflammatory factors. As a result, it often results in unfavorable glucose metabolism and type-2 diabetes.

**Table 2** The regression models for visceral adipose tissue with clinical continuous and dichotomous risk variables for subjects without overt diabetes (N = 512)

| PCF (ml) | TAT (ml) |
|----------|----------|
|          | β-Coef. p value | β-Coef. p value |
| Age, years | 0.34 <0.001 | 0.34 <0.001 |
| Gender, female | −0.19 <0.001 | −0.38 <0.001 |
| SBP, mmHg | 0.3 <0.001 | 0.35 <0.001 |
| BMI, kg/m² | 0.55 <0.001 | 0.57 <0.001 |
| BSA, m² | 0.45 <0.001 | 0.51 <0.001 |
| WC, cm | 0.58 <0.001 | 0.64 <0.001 |
| Body Fat, % | 0.3 <0.001 | 0.2 <0.001 |
| SBP, mmHg | 0.3 <0.001 | 0.35 <0.001 |
| Fasting glucose, mg/dL | 0.22 <0.001 | 0.24 <0.001 |
| Total cholesterol, mg/dL | 0.08 0.05 | 0.25 0.216 |
| HDL cholesterol, mg/dL | −0.24 <0.001 | −0.36 <0.001 |
| Triglyceride, mg/dL | 0.18 <0.001 | 0.26 <0.001 |
| LDL cholesterol, mg/dL | 0.12 0.004 | 0.12 0.004 |
| eGFR, ml/min/1.73 m² | −0.12 0.04 | −0.22 <0.001 |
| Hypertension | 0.18 <0.001 | 0.22 <0.001 |
| Hyperlipidemia | 0.09 0.015 | 0.08 0.027 |
| Exercise | −0.08 0.019 | −0.11 0.02 |
| Alcohol use | 0.004 0.0935 | 0.1 0.015 |
| Smoking | 0.06 0.082 | 0.12 0.001 |

BMI body mass index, HbA1c glycosylated hemoglobin, TG triglyceride, LDL cholesterol low-density cholesterol, HDL cholesterol high-density cholesterol, eGFR estimated glomerular filtration rate, WC waist circumference.

**Table 3** The association of visceral adipose tissue with HOMA-IR, and Hs-CRP in subjects without overt diabetes (N = 512)

| PCF (ml) | TAT (ml) |
|----------|----------|
|          | HOMA-IR Hs-CRP | HOMA-IR Hs-CRP |
|          | β-Coef. p value | β-Coef. p value | β-Coef. p value | β-Coef. p value |
| Un-adjusted Model | 0.21 (<0.001) | 0.16 (0.005) | 0.43 (<0.001) | 0.27 (<0.001) |
| Adjusted for BMI | Age, gender, BMI | 0.11 (0.089) | 0.12 (0.582) | 0.42 (<0.001) | 0.17 (0.021) |
| Adjusted for BSA | Age, gender, BSA | 0.08 (0.266) | 0.14 (0.373) | 0.36 (0.005) | 0.22 (0.024) |
| Adjusted for WC | Age, gender, WC | 0.06 (0.087) | 0.11 (0.034) | 0.41 (<0.001) | 0.12 (0.002) |
| Adjusted for body fat % | Age, gender, body fat % | 0.05 (0.514) | 0.06 (0.482) | 0.38 (<0.001) | 0.20 (0.038) |

BMI body mass index, HbA1c glycosylated hemoglobin, TG triglyceride, LDL cholesterol low-density cholesterol, HDL cholesterol high-density cholesterol, eGFR estimated glomerular filtration rate, WC waist circumference.

Clinical variables included age, sex, systolic blood pressure, fasting glucose, triglyceride, HDL cholesterol, exercise, alcohol use, smoking, and hypertension or hyperlipidemia treatment.
ever, a comprehensive characterization of pericardial and differences in leptin, adiponectin, and IL-6 secretion. How-

ted with significantly higher pericardial and peri-aortic

tissue burden in this population may help to clarify these

dysfunction. Future longitudinal studies of visceral adipose

tissue may exert a more significant systemic effect than peri-
cardial adipose tissue.

**Conclusions**

Our data indicated that pre-diabetic status was associ-
ated with significantly higher pericardial and peri-aortic
adipose tissues than normal subjects, which is actually comparable to established diabetic patients. In addition,
in subjects without established diabetes, visceral fat adja-
cent to the aorta seemed to exert effects on insulin
resistance and systemic inflammation. We believe that the major implications of this study are as follows: (1) increased specific regional visceral fat deposits may be related to pre-diabetes and could be used as additional information for cardiovascular risk stratification during the early stages of glucose dysfunction; (2) peri-aortic fat may exert a more significant systemic effect than peri-
cardial adipose tissue.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contribution**

FY, CY, CH and BB have substantial contributions to conception and design. CH, TW, YH, CL, JK, YW have participated in acquisition of data, or analysis and interpretation of data. HB, CJH, HY, JJL, RC have been involved in drafting the manuscript and revising it. All authors read and approved the final manuscript.

**Acknowledgements**

We would like to thank Ms. Jasmine Yeh who provided technique support of software on behalf of TeraRecon, Inc.

**Funding sources**

This work was supported in part by a research grant from Mackay Memorial Hospital and NSC 101-2314-B-195-020.

**Author details**

1Department of Radiology, Mackay Memorial Hospital, Taipei, Taiwan.
2Department of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan.
3Department of Anesthesiology, Peking University First Hospital, Beijing, China.
4Cardiovascular Department, University Hospitals Case Medical Center, Cleveland, USA.
5Graduate Institute of Health Care Organization Administration, College of Public Health National Taiwan University, Taipei, Taiwan.
6Health Evaluation Center, Mackay Memorial Hospital, Taipei, Taiwan.
7Department of Medical Technology, Yuanpei University of Science and Technology, Hsin-Chu, Taiwan.
8Department of Internal Medicine, Division of Cardiology, Mackay Memorial Hospital, Taipei, Taiwan.
9Department of Medicine, Mackay Medical College, and Mackay Medicine Nursing and Management College, Taipei, Taiwan.
10Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.
11Diagnostic Medical Sonography, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts, USA.
12Noninvasive Cardiovascular Research, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA.
13Department of Radiology, Cardiovascular MRI and CT Program, Baptist Cardiac and Vascular Institute, Miami, FL, USA.

Received: 10 August 2013 Accepted: 28 October 2013

**Published: 11 November 2013**

**References**

1. Marinou K, Tousoulis D, Antonopoulous AS, Stefanadi E, Stefanadis C: Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol 2010, 138(1–3):8–13.
2. Wang CP, Hsu HL, Hung WC, Yu TH, Chen YH, Chu CA, Lu LF, Chung FM, Shin SJ, Lee YJ: Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol (Oxf) 2009, 70(6):876–882.
3. Bays HE: Adiposopathy is “sick fat” a cardiovascular disease? J Am Coll Cardiol 2011, 57(25):2461–2473.
4. Buyschaert M, Bergman M: Definition of prediabetes. Med Clin North Am 2011, 95(2):289–297. vii.
5. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L: Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000, 23(4):465–471.

6. Yun CH, Lin TY, Wu YJ, Liu CC, Kuo JY, Yeh HI, Yang FS, Chen SC, Hou CJ, Bezerra HG, et al: Pericardial and thoracic peri-aortic adipose tissues contribute to systemic inflammation and calcified coronary atherosclerosis independent of body fat composition, anthropometric measures and traditional cardiovascular risks. Eur J Radiol 2012, 81:749–756.

7. Standards of medical care in diabetes—2007. Diabetes Care 2007, 30(Suppl 1):S1–S14.

8. Lehman SJ, Massaro JM, Schlett CL, O’Donnell CJ, Hoffmann U, Fox CS: Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: the Framingham heart study. Atherosclerosis 2010, 210(2):656–661.

9. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U: Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham heart study. Eur Heart J 2009, 30(7):850–856.

10. Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria. The DECODE study group. European diabetes epidemiology group. Collaborative analysis of diagnostic criteria in Europe. Lancet 1999, 354(9179):617–621.

11. Stancakova A, Kuulasmaa T, Paananen J, Jackson AU, Bonnycastle LL, Collins FS, Boehnke M, Kuusiisto J, Laakso M: Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes 2009, 58(9):2129–2136.

12. Iacobellis G, Barbaro G, Gerstein HC: Relationship of epicardial fat thickness and fasting glucose. Int J Cardiol 2008, 128(3):424–426.

13. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O’Donnell CJ, Fox CS: Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham heart study. Circulation 2008, 117(5):605–613.

14. Seyedi JC, Han TS, Feikens EJ, Lean ME: Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med 1997, 242(5):401–406.

15. Bays HE: “Sick fat,” metabolic disease, and atherosclerosis. Am J Med 2009, 122(1 Suppl):S26–S37.

16. Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman NA, Kitabchi AE, Schor ABl, Rodbard HW: Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract 2008, 62(10):1474–1483.

17. McGarry JD: Bantering lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51(17):17–18.

18. Pi-Sunyer FX: The epidemiology of central fat distribution in relation to disease. Nutr Rev 2004, 62(7 Pt 2):S120–S126.

19. Despres JP, Lemieux I, Prud’homme D: Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001, 322(7288):716–720.

20. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keijer EA, Johnson AG, et al: Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003, 108(20):2460–2466.

21. Spiroulou SG, Kostopoulos CG, Varakis JN, Papadaki HH: Adipokines in peri-aortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb 2010, 17(2):115–130.

22. Greif M, Becker A, von Ziegler F, Lebherz C, Lehnrue C, Broedl UC, Titzus J, Parhofer K, Becker C, Raiser M, et al: Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29(5):781–786.